Foghorn Therapeutics Inc. (FHTX) has been beaten down lately with too much selling pressure. While the stock has lost 23.1% ...

Foghorn Therapeutics Inc. (FHTX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...

Foghorn Therapeutics (FHTX) announced its strategic objectives for 2025. First-in-class oral selective SMARCA2 inhibitor, FHD-909, advancing in ...

A FORMER foghorn testing station has been transformed into a stunning luxury home and you can book a stay for just £375. The ...

Foghorn Therapeutics shares are trading lower by 20.2% during Monday's session. The company announced it will discontinue independent development of its FHD-286 program. Foghorn Therapeutics Inc ...

Before sailing off into the sunset from Charleston for the final time this past weekend, the Carnival Sunshine had one final ...

First-in-class oral selective SMARCA2 (BRM) inhibitor, FHD-909 (LY4050784), advancing in Phase 1 trial for SMARCA4 mutated cancers, with ...

Foghorn Therapeutics Inc. (FHTX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...

Jan. 13, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting ...